文献速递肝病消化道肿瘤与早癌

ALBI-6:整合ALBI与白介素-6的新型预后评分用于阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者

ALBI-6-A Novel Prognostic Score Combining ALBI and Interleukin-6 in Patients With HCC Treated With Atezolizumab and Bevacizumab.
PubMed 文献 · Aliment Pharmacol Ther · 2026-10-08

这项多中心回顾性队列研究纳入216例接受一线阿替利珠单抗联合贝伐珠单抗治疗的晚期肝细胞癌患者,基线白介素-6升高与更差的总生存相关且独立于肿瘤和临床因素。基于Cox回归构建的ALBI-6评分在验证集(n=90)中一致性指数为0.716,可将患者分为三个生存显著不同的风险组(log-rank p=0.002),且判别力显著优于mALBI(p=0.040),并在所有评估时间点显著优于CRAFITY评分。

要点

  • 基线IL-6升高与晚期HCC免疫联合治疗患者更差的总生存独立相关。
  • ALBI-6评分在验证集中C指数为0.716,可区分三个生存显著不同的风险组。
  • ALBI-6判别力显著优于mALBI(p=0.040),并在各时间点显著优于CRAFITY。

核心结论

  • ALBI-6将系统性炎症与肝功能整合为简单复合指数,可对接受免疫治疗的晚期肝细胞癌患者进行有意义的风险分层。

研究设计与样本

  • 多中心回顾性队列研究,纳入216例接受一线阿替利珠单抗联合贝伐珠单抗治疗的晚期肝细胞癌患者。
  • 队列随机分为训练集(n=98)和验证集(n=90),ALBI-6通过Cox回归推导并与多个已建立预后评分比较。
  • 白介素-6在基线、首次缓解、最佳缓解和进展时测量。

主要发现

  • 基线白介素-6升高与更差的总生存一致相关,校正肝外播散、血管侵犯、甲胎蛋白、体能状态和肝功能分级后仍为独立预后因素。
  • 验证集中ALBI-6的一致性指数为0.716,将患者分为三个生存显著不同的风险组(log-rank p=0.002)。
  • ALBI-6显著优于改良白蛋白-胆红素分级(p=0.040),其余比较评分仅数值上更高。
  • 在全体队列的单独分析中,ALBI-6在所有评估时间点显著优于CRAFITY评分。
  • Bootstrap验证确认模型稳定性。

临床怎么用

  • 对于接受阿替利珠单抗联合贝伐珠单抗一线治疗的晚期肝细胞癌患者,可考虑用基线白介素-6联合ALBI分级进行基线风险分层。

局限性

  • 本文为回顾性队列研究,ALBI-6需前瞻性外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Despite widespread use of combination immunotherapy in advanced liver cancer, reliable biomarkers for baseline risk stratification remain lacking. The inflammatory cytokine interleukin-6 has established prognostic relevance in this cancer. We investigated the prognostic value of interleukin-6 and developed a combined score (ALBI-6) integrating interleukin-6 with albumin-bilirubin grade, a marker of liver function. METHODS: In this multicentre retrospective cohort study, 216 patients with advanced hepatocellular carcinoma treated with first-line atezolizumab plus bevacizumab were analysed. Interleukin-6 was measured at baseline, first response, best response, and progression. The cohort was randomly divided into a training set (n = 98) and a validation set (n = 90). ALBI-6 was derived using Cox regression and evaluated against several established prognostic scores. RESULTS: Elevated baseline interleukin-6 was consistently associated with worse overall survival and remained independently prognostic after adjustment for tumour and clinical factors (extrahepatic spread, vascular invasion, alpha-fetoprotein, performance status, liver function class). In the validation cohort, ALBI-6 achieved a concordance index of 0.716 and separated patients into three risk groups with significantly different survival (log-rank p = 0.002); ALBI-6 was significantly more discriminative than one comparator score (modified albumin-bilirubin grade, p = 0.040), with numerically higher performance than the remaining comparators. In a separate analysis of the full cohort, ALBI-6 significantly outperformed the CRAFITY score at all assessed time points. Bootstrap validation confirmed model stability. CONCLUSIONS: ALBI-6 integrates systemic inflammation and liver function into a simple composite index enabling meaningful risk stratification in patients with advanced hepatocellular carcinoma treated with immunotherapy. Prospective external validation is warranted.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bark P, Wiesmann L, Gairing SJ, et al. ALBI-6-A Novel Prognostic Score Combining ALBI and Interleukin-6 in Patients With HCC Treated With Atezolizumab and Bevacizumab. Aliment Pharmacol Ther. 2026. PMID: 42850750. doi:10.1111/apt.71012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。